Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 31, 2023 - Issue 1
Submit an article Journal homepage
192
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Comparing the Efficacy of Intravitreal Dexamethasone and Time-displaced Fluocinolone Acetonide on Central Retinal Thickness in Patients with Uveitis

Matthias Kriegela Department of Ophthalmology, St. Franziskus Hospital, Muenster, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4528-5711View further author information
, MDORCID Icon,
Arnd Heiligenhausa Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany;b Ophthalmology, University of Duisburg-Essen, Essen, GermanyORCID Iconhttps://orcid.org/0000-0002-1726-8973View further author information
, MDORCID Icon &
Carsten Heinza Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany;b Ophthalmology, University of Duisburg-Essen, Essen, GermanyORCID Iconhttps://orcid.org/0000-0002-2814-4327View further author information
, MDORCID Icon
Pages 168-174 | Received 21 May 2021, Accepted 28 Sep 2021, Published online: 26 Jan 2022

References

  • Rypdal V, Glerup M, Songstad NT, et al. Uveitis in Juvenile idiopathic arthritis: 18-year outcome in the population-based nordic cohort study. Ophthalmology. 2021;128:598–608. Published online August 2020. doi:10.1016/j.ophtha.2020.08.024.
  • Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with Juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:4. doi:10.1016/j.ajo.2006.11.025.
  • Zhao C, Zhang M. Immunosuppressive treatment of non-infectious uveitis: history and current choices. Chin Med Sci J. 2017;32(1):48–61. doi:10.24920/J1001-9242.2007.007.
  • Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018;125:193–202. doi:10.1016/j.ophtha.2017.08.007.
  • Agrawal H, Doan H, Pham B, et al. Systemic immunosuppressive therapies for uveitis in developing countries. Indian J Ophthalmol. 2020;68(9):1852. doi:10.4103/ijo.ijo_1548_20.
  • Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophthalmic indications: current status and outlook. BioDrugs. 2013;27(4):347–357. doi:10.1007/s40259-013-0022-9.
  • Soheilian M, Rabbanikhah Z, Ramezani A, et al. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther. 2010;26(2):199–205. doi:10.1089/jop.2009.0093.
  • Rahimi M, Shahrzad SS, Banifatemi M. Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema. Iran J Immunol. 2012;9(2):136–144. doi:IJIv9i2A7.
  • Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina. 2011;31(1):111–118. doi:10.1097/IAE.0b013e3181e378af.
  • Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol. 2009;148:2. doi:10.1016/j.ajo.2009.03.028.
  • Reddy AK, Cabrera M, Yeh S, et al. Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: twelve-month outcomes. Retina. 2014;34(12):2431–2438. doi:10.1097/IAE.0000000000000274.
  • Hasanreisoğlu M, Ö H, Ö K, et al. Intravitreal dexamethasone implant in the treatment of non-infectious uveitis. Turk J Ophthalmol. 2019;49(49):250–257. doi:10.4274/tjo.galenos.2019.81594.
  • Palla S, Biswas J, Nagesha C. Efficacy of ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol. 2015;63(10):767–770. doi:10.4103/0301-4738.171505.
  • Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
  • Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–610. doi:10.1016/j.ophtha.2018.10.033.
  • Mathis T, Cerquaglia A, Weber M, et al. Real life study in uveitis treated with dexamethasone implant. Retina. Published online 2020. doi:10.1097/IAE.0000000000002901.
  • Jaffe GJ, Pavesio CE. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology. 2020;127(10):1395–1404. doi:10.1016/j.ophtha.2020.04.001.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
  • Tomkins-Netzer O, Taylor SRJ, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121:1649–1654. doi:10.1016/j.ophtha.2014.02.003.
  • Mustafi D, Do BK, Rodger DC, Rao NA. Relationship of epiretinal membrane formation and macular edema development in a large cohort of uveitic eyes. Ocul Immunol Inflamm. 2021;29:915–921. doi:10.1080/09273948.2019.1704026.
  • Lehpamer B, Moshier E, Pahk P, et al. Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol. 2014;157(5):1048–1055. doi:10.1016/j.ajo.2014.01.020.
  • Tomkins-Netzer O, Taylor SRJ, Lightman S. Long-term clinical and anatomic outcome of birdshot chorioretinopathy. JAMA Ophthalmol. 2014;132(1):57–62. doi:10.1001/jamaophthalmol.2013.6235.
  • Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37(7):1352–1359. doi:10.1097/IAE.0000000000001369.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.